Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan changes IOL manufacturing process to address lens yellowing problem.

This article was originally published in The Gray Sheet

Executive Summary

ALLERGAN IOL MANUFACTURING CHANGES MADE TO PREVENT LENS YELLOWING, a problem that led to a voluntary recall of the devices. AMO PhacoFlex II Model SI-30NB intraocular lenses, manufactured between July 13, 1995 and Oct. 31, 1995, "have a somewhat yellow appearance" that was caused by the packaging material used to ensure sterility during that time period, the firm explains in a Feb. 5 voluntary recall notice. An investigation by the firm "led to manufacturing changes to prevent this phenomenon from recurring," the firm states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel